Clinical Trials

31 enrolled

Phase EARLY_PHASE1 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Disease Progression

NCT05076513 2026-03-09

Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma

42 enrolled

Phase 1/2 Active not recruiting

Glioblastoma, Glioma

NCT03830918 2026-02-12

Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

59 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04068753 2026-02-10

STAR

66 enrolled

Phase EARLY_PHASE1 Active not recruiting

Uterine Cervical Neoplasms

NCT05406700 2026-02-09

Niraparib In Recurrent IDH 1/2 Gliomas

16 enrolled

Glioma

NCT03601923 2026-01-28

Niraparib in Patients With Pancreatic Cancer

Phase 1/2 Active not recruiting

32 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03368729 2026-01-23

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

46 enrolled

Breast

Breast Neoplasms

NCT04992013 2026-01-23

Niraparib in Tumors Metastatic to the CNS

20 enrolled

Neoplasm Metastasis, Central Nervous System Neoplasms

NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

BreastGastrointestinalGynecologic

18 enrolled

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT04221503 2026-01-08

Niraparib/TTFields in GBM

30 enrolled

Glioblastoma

NCT05689021 2026-01-07

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

8 enrolled

Prostatic Neoplasms

NCT03983993 2026-01-05

NIPAVect

26 enrolled 8 charts

Gastrointestinal

Colorectal Neoplasms

NCT04592237 2025-12-23

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

120 enrolled

Prostatic Neoplasms

NCT04701307 2025-12-15

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

48 enrolled

EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT05515575 2025-10-20

A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA

8 enrolled

Sarcoma

NCT03945721 2025-09-29

UNITY

21 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04030559 2025-08-26

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

11 enrolled

Prostatic Neoplasms

NCT04584255 2025-07-28

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Phase 1/2 Active not recruiting

62 enrolled

Breast

Breast Neoplasms

NCT04194554 2025-06-04

ASCLEPIuS

102 enrolled

Prostatic Neoplasms

NCT04502602 2025-05-04

iNNOVATE

18 enrolled

Ovarian Neoplasms

NCT04507841 2024-12-17

Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

67 enrolled

Ovarian Neoplasms

NCT04185831 2024-08-22

MEGALiT

167 enrolled

Other solid neoplasm

Solid Tumor

NCT04313504 2024-08-01

Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC